Search results
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
Thursday 20 November 2025, 7.00pm - 8.00pm - via Zoom - Come and join us for our latest meeting where we will be sharing some useful tech that was showcased at this years London Sight Village being held at the ILEC Conference Centre.
Colin McArthur re-joined the board in 2024 after serving as a trustee between January 2008 and September 2019.
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Thursday 11 December 2025, 12.00pm - 2.00pm - In-person - Come and join Mark Baxter and the Buckinghamshire group for our last social meet up of the year over a festive lunch at The White Hart pub in Aylesbury town centre.
Thursday 4 December 2025, 7.00pm - 8.30pm - via Zoom - Come and join Martik and the group for our festive Young Adults online social catch up where we are delighted to be joined by Emma Quigley & Joe Maguire from Blind in Business.
TPT and Sight Loss Councils: Cut it back campaign
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
